Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) are the first-line guideline-recommended therapy since they are as effective and overall safer than warfarin in pre...

Full description

Bibliographic Details
Main Authors: Alessandra M. Campos-Staffico, Michael P. Dorsch, Geoffrey D. Barnes, Hao-Jie Zhu, Nita A. Limdi, Jasmine A. Luzum
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
atrial fibrillation
bleeding
anticoagulation
pharmacogenetics
DOAC
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1007113/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1007113/full

Similar Items